Chonluten Peptide Dosage Chart: 2mg Course, Vial Math

Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG), and there is no clinically established human dose for it. A widely circulated practitioner peptide reference lists it with the other Khavinson bioregulators on one shared protocol: a 20mg vial with 2mL of bacteriostatic water, 2mg (20 units) once daily for 30 consecutive days, then two months off, two to three times a year. Self-reported community sources also describe 10-20 day courses.

Chonluten is sold as a bronchial and lung bioregulator, but its indexed evidence is one cell-culture study and a modeling paper. The rat lung studies people often attach to it belong to a different peptide, Bronchogen. Every number below is a reported convention, not a dose from Chonluten research.

Research-context information only. Chonluten is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Chonluten is a three-amino-acid peptide from the St. Petersburg bioregulator program. Its vendor lists it as C11H17N3O8 (319.27 g/mol, CAS 75007-24-8), with the synonym T-34. This guide covers the reported course, the reconstitution math, and the source of each figure.

Quick Reference: Practitioner-Reported Protocol

Where the 2mg figure comes from: it is the shared bioregulator line in a practitioner peptide reference (the Jay Campbell / Hunter Williams cheat sheet). It was not taken from a Chonluten study. For the compound profile and current vendor pricing, see the Chonluten peptide page.

Cycling Details

The pulsed course follows the Russian bioregulator convention: short peptide exposure, followed by a long break. Under the developers' theory, a short peptide acts as a brief gene-regulatory signal rather than a drug that needs steady levels (Khavinson & Anisimov, 2009). Practitioner references run 30 days on and two months off. Self-reported community protocols often use 10-20 day courses repeated a few times a year. Neither schedule has been tested for Chonluten in people.

Routes of Administration

• Subcutaneous (SC): the route community sources most often describe for the reconstituted 20mg research vial.
• Intramuscular (IM): described less often in community sources, as a carry-over from older Russian injectable bioregulator practice.
• Oral capsules: sold in some markets under bioregulator names. They are a different format from the injectable research vial.

No route has been validated for Chonluten. US vendors sell it labeled for laboratory research only.

Reconstitution Quick Reference

The community-circulated arithmetic: 20mg ÷ 2mL = 10mg/mL, so 2mg is 0.2mL, or 20 units on a 100-unit insulin syringe. By that arithmetic, a 30-day course at the reported amount would total 60mg, or three 20mg vials. Community notes describe swirling gently rather than shaking, then refrigerating at 2-8°C.

These figures report how community sources describe the arithmetic. They are not a preparation instruction. Vendors label these vials for research use only; the schedules on this page are community- and practitioner-reported, not labeled directions.

Affiliate disclosure: vendor links in this article are affiliate links. The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? The Chonluten source we track publishes certificates of analysis; see our Chonluten sources page.

Where These Numbers Come From

None of the dose figures above comes from a Chonluten study. No such dose-finding study exists. The 2mg course is a practitioner convention applied to the whole Khavinson family, and the shorter courses are community convention.

The one cell study. In 2022 an Italian group, working with the Khavinson institute, tested five Khavinson peptides on THP-1 human monocytic cells. The peptides were Epitalon, Vilon, Thymogen, Thymalin and the Chonluten tripeptide. The authors describe Chonluten as derived from bronchial epithelial cells. It inhibited TNF production by monocytes exposed to bacterial lipopolysaccharide. All five peptides lowered TNF and IL-6 in differentiated cells and reduced monocyte adhesion to activated endothelial cells (Avolio et al., 2022, PMID 35408963). This was a dish experiment at fixed concentrations. It gives no basis for a human dose.

The modeling paper. A 2023 computer-docking study from the originating institute ranked EDG among the most effective ligands of the LAT1, LAT2 and PEPT1 transporters. The authors speculated that this transporter binding could relate to antitumor effects reported for EDG and similar peptides (Khavinson et al., 2023, PMID 36979488). It is a modeling result, not a measured effect in tissue.

The broader theory. The developers' model holds that ultrashort peptides enter cell nuclei and shift gene expression by binding DNA and histones (Khavinson et al., 2021, PMID 34834147). It is a single-group hypothesis, demonstrated mostly in vitro.

What is missing. We found no PubMed-indexed study of Chonluten in animals or people, no lung-injury model, and no pharmacokinetic data. Some secondary sources say the developers have also described EDG as a gastric- or stress-protective peptide. We found no indexed study supporting either role, so this guide does not report one.

Chonluten vs Bronchogen, in brief

The two names are often confused because both are sold for the airways.

Our Bronchogen dosing guide covers the tetrapeptide. Its safety evidence is in Bronchogen Side Effects: What the Evidence Shows (2026).

Extract versus synthetic. Chonluten is sometimes described as a bronchial-tissue extract. The 20mg research vial is the synthetic tripeptide. The Khavinson program made tissue-derived polypeptide complexes and short synthetic peptides as separate products, and data on one do not carry over to the other.

Stacking Protocols

Community sources occasionally run Chonluten alongside other Khavinson-family peptides in the same course window. The pairings below are self-reported and have no trial support.

No Chonluten combination has been studied in animals or people.

Side Effects & Safety

• No human safety data exist for Chonluten. It is sold labeled "not for human consumption."
• No animal toxicity study of EDG appeared in our PubMed search, so even preclinical safety is uncharacterized.
• Injection-site redness or soreness is the effect most often mentioned in self-reported community sources.
• Long-term effects of repeated courses are unknown.
• Sterile handling and reconstitution hygiene are the practical concerns community sources raise most often.

mg to Units Conversion

On a U-100 insulin syringe, 1 unit is 0.01mL. The draw depends on how much water went into the vial.

Dilution A: 20mg vial + 2mL BAC water (10mg/mL)

Dilution B: 20mg vial + 1mL BAC water (20mg/mL), a more concentrated mix with smaller draw volumes

Only the 2mg row matches the practitioner figure; the other rows are arithmetic reference points, not amounts a cited source reports. These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.